June 16th, 2025
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
June 16th, 2025
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
June 2nd, 2025
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
May 19th, 2025
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
May 12th, 2025
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema
April 1st, 2025
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
March 18th, 2025
Groundbreaking Step in Battling Angioedema at UC San Diego
March 18th, 2025
Making our voices heard for Rare Disease Week and beyond
March 5th, 2025
AAAAI: Berotralstat reduces monthly hereditary angioedema attack rates in children
March 3rd, 2025
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
March 3rd, 2025
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
February 7th, 2025
Clinical validity of dried blood spot assay for the measurement of functional C1 inhibitor in angioedema due to C1 inhibitor deficiency
January 13th, 2025
Pharvaris Outlines 2025 Strategic Priorities
January 10th, 2025
The adolescent experience of hereditary angioedema: a qualitative study of disease burden and treatment experience
January 6th, 2025
Survey reveals difficulties managing HAE attacks regardless of treatment
November 4th, 2024
FDA accepts donidalorsen NDA for prophylactic hereditary angioedema
October 28th, 2024
Most HAE patients attack-free after NTLA-2002 treatment in trial
October 16th, 2024
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
October 14th, 2024
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
October 10th, 2024
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
October 8th, 2024
Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy
October 3rd, 2024
US HAEA - Development and validation of a US quality of life instrument for hereditary angioedema due to C1 inhibitor deficiency
September 30th, 2024
Life quality declines as frequency of HAE attacks rises, study finds
September 5th, 2024
Pharvaris Presents Data at the Bradykinin Symposium 2024
September 5th, 2024
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
September 5th, 2024
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
September 3rd, 2024
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
August 28th, 2024
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 14th, 2024
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12th, 2024
STAR-0215 has a new generic name. Introducing…navenibart (nah-VEN-eh-bart)
August 12th, 2024
Phase 3 trial of NTLA-2002, gene-editing therapy, possible in 2024
July 23rd, 2024
Grassroots Initiative Helping Clinicians Better Treat Rare Disease Patients
July 8th, 2024
KalVista launches sebetralstat trial in young children with HAE
July 3rd, 2024
Normalization of C1 Inhibitor in a Patient with Hereditary Angioedema
June 18th, 2024
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
June 4th, 2024
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
May 31st, 2024
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
May 31st, 2024
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
May 13th, 2024
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
May 8th, 2024
The US Hereditary Angioedema Association Scientific Registry: hereditary angioedema demographics, disease severity, and comorbidities
May 8th, 2024
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
April 10th, 2024
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 4th, 2024
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 4th, 2024
Most HAE patients surveyed say they can predict swelling attacks
March 21st, 2024
Study Data Suggests Sustained Safety, Efficacy of Lanadelumab in Adolescents With HAE
March 18th, 2024
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
March 18th, 2024
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
February 27th, 2024
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 22nd, 2024
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 15th, 2024
Sebetralstat found effective in trial as on-demand treatment for HAE
February 5th, 2024
Single dose of NTLA-2002 seen to reduce monthly HAE attacks 95%
February 1st, 2024
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
February 1st, 2024
Angiodema: Gene therapy blocks painful hereditary disorder
January 31st, 2024
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
January 22nd, 2024
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment
of HAE Attacks
January 12th, 2024
The road less traveled highlights the importance of being informed
January 11th, 2024
Long-term use of attenuated androgens may increase health risks
December 26th, 2023
Switching from androgens to Orladeyo reduces HAE swelling attacks
December 21st, 2023
Long-term Orladeyo safe, effective in HAE patients: Trial data
December 18th, 2023
Garadacimab up for approval as HAE therapy in US, Europe
December 18th, 2023
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary
angioedema
December 6th, 2023
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
December 4th, 2023
Phase 3 trial of sebetralstat meets targeted number of treated attacks
November 30th, 2023
STAR-0215 shows promise as HAE treatment in new Phase 1 trial data
November 27th, 2023
HAE attacks start resolving in under 30 minutes with PHVS416 in trial
November 23rd, 2023
Examining the Impact of the COVID-19 Pandemic on Individuals Affected by Hereditary Angioedema Type I and Type II
November 15th, 2023
Two-Year Analysis of the Donidalorsen Phase 2 Open-Label Extension Study in Patients With Hereditary Angioedema
November 13th, 2023
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
November 13th, 2023
Fewer HAE attacks, life quality gains seen with donidalorsen at 2 years
November 9th, 2023
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
October 26th, 2023
Despite preventive treatment, HAE patients require on-demand care
October 12th, 2023
Patient feedback helps in design of Phase 3 trial of oral sebetralstat
October 7th, 2023
Hereditary Angioedema patient experiences of medication use and emergency care
September 22nd, 2023
When periods of good health don’t lead to needed rest
August 31st, 2023
Orladeyo effective in 3 people with HAE of unknown origin
August 17th, 2023
FDA approves new generic version of Firazyr for HAE
August 14th, 2023
Patient enrollment for deucrictibant CHAPTER-1 trial completed
August 11th, 2023
Why there’s power in sharing our angioedema stories
August 10th, 2023
Phase 3 trial of gene-editing therapy NTLA-2002 for HAE slated for 2024
July 27th, 2023
HAE patients can see early signs of attacks, need for prompt treatment
July 27th, 2023
HAE patients can see early signs of attacks, need for prompt treatment
July 20th, 2023
Long-Acting Plasma Kallikrein Inhibitor Gets Fast Track Status for Hereditary Angioedema
July 17th, 2023
BioCryst to Participate in the 2023 US HAEA National Summit
July 14th, 2023
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
July 14th, 2023
I finally understand my daughter’s fear of missing out
July 13th, 2023
Long-term Takhzyro treatment linked to lower US healthcare costs
June 30th, 2023
How schools (too often) need to be educated about HAE
June 26th, 2023
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
June 23rd, 2023
Dealing with my daughter’s HAE led to an epiphany about my mother
June 22nd, 2023
PHVS416 found to quickly ease HAE swelling symptoms in trial
June 15th, 2023
9 of 10 HAE patients attack free with NTLA-2002, gene-editing therapy
June 11th, 2023
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
June 2nd, 2023
The remedy to feeling small is finding your rare disease community
June 1st, 2023
Positive donidalorsen late-stage clinical progress in HAE announced by Ionis
June 1st, 2023
Ionis announces positive donidalorsen late-stage clinical progress in HAE
May 26th, 2023
How the space-time continuum is affected by caregiving
May 19th, 2023
How being an HAE caregiver led me to awareness and advocacy
May 11th, 2023
Plasma donors desperately needed to save lives
May 9th, 2023
Dosing of HAE gene-editing therapy NTLA-2002 begins in Phase 2 study
May 4th, 2023
Prodromal Symptoms of Hereditary Angioedema (HAE) attacks: a patient survey in UK & Spain
May 4th, 2023
Under-the-skin injections found to ease angioedema in pregnancy
May 1st, 2023
Orladeyo helps HAE patients spend more days attack-free: Trial analysis
April 28th, 2023
Ellington mother and son talk about their battle with hereditary angioedema
April 28th, 2023
How kid logic complicates effective HAE treatment
April 24th, 2023
US health insurance problems affect well-being of HAE patients: Survey
April 22nd, 2023
Managing Diagnosis, Treatment, and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor
April 21st, 2023
Providers urged to do more to help patients access care for hereditary angioedema
April 14th, 2023
The frustrating conversations with people who don’t understand HAE
April 13th, 2023
Takhzyro linked to long-term quality of life gains in HAE study
April 10th, 2023
PHVS416 shows promise in treating HAE swelling attacks: Trial data
April 10th, 2023
FDA Clears First Study of CRISPR Gene-Editing in Human Patients
April 7th, 2023
Learning to embrace my support team after an HAE diagnosis
April 6th, 2023
Multiple obstacles make hereditary angioedema diagnosis, treatment difficult
April 6th, 2023
Preventive therapy found to reduce number, not severity of HAE attacks
April 5th, 2023
Survey of Allergists/Immunologists Reveals Management of Hereditary Angioedema Differs by Region
April 3rd, 2023
Poorly controlled HAE carries heavy burden, affecting life quality
April 1st, 2023
‘PEEPbra’ sculpture aims to raise awareness about rare diseases during annual PEEPshow in Westminster
March 24th, 2023
Oh, the relief that comes when an educated expert arrives to help
March 20th, 2023
Diagnosing and treating HAE most challenging across rural US
March 18th, 2023
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
March 16th, 2023
Insurance delays, denials negatively impact patients with hereditary angioedema
March 16th, 2023
CSL Behring to seek approval of garadacimab this year
March 6th, 2023
Phase 2 trial of NTLA-2002, HAE gene-editing therapy, to enroll in US
March 2nd, 2023
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
February 28th, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
February 27th, 2023
Debajyoti Ghosh, PhD: Potential Benefits of Treating Hereditary Angioedema Early Symptoms
February 27th, 2023
Genetic analysis reveals recurrent HAE with normal C1-INH: Study
February 26th, 2023
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
February 24th, 2023
How to guard against the crash after doing too much
February 22nd, 2023
HAE exacerbations secondary to insurance barriers: A common, yet avoidable, trigger
February 20th, 2023
Survey of US doctors estimates prevalence of HAE-nl-C1INH
February 17th, 2023
The unsung heroes of hereditary angioedema treatment
February 16th, 2023
Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain
February 16th, 2023
Identifying the Zebras: Key Insights on Chronic Abdominal Pain in HAE
February 14th, 2023
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
February 9th, 2023
Phase 1b/2 trial of STAR-0215 is now enrolling HAE patients
February 7th, 2023
New Chief Takes the Helm at the Life Raft Group as GIST Research Continues to Expand
February 3rd, 2023
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
February 1st, 2023
Bright Ideas for Rare Disease Day 2023
January 30th, 2023
I wrote about high-priced drugs for years. Then my toddler needed one.
January 27th, 2023
Why Complicate Things When There’s a Simple Explanation?
January 26th, 2023
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in
Pediatric Patients with Hereditary Angioedema
January 25th, 2023
Ground-breaking gene-editing treatment leaves patient feeling like they have 'a new body'
January 24th, 2023
A Rare Public Health Challenge
January 23rd, 2023
Bowel Surgery Necessary for HAE Patient After Therapy Fails
January 20th, 2023
Ignoring the Symptoms of Illness That Have Always Been There
January 16th, 2023
‘A magic wand’: World-first NZ gene-editing trial may offer cure for debilitating disorder
January 15th, 2023
Hereditary Angioedema with Normal C1 Esterase Inhibitor Refractory to Long-Term Prophylaxis: A Case Report
January 13th, 2023
How Endless Circles Can Lead to Frustration
January 12th, 2023
6 New Angioedema Centers Now Part of ACARE Global Network
January 6th, 2023
The Most Important New Year’s Resolution for Caregivers
December 24th, 2022
Dealing with a life-changing illness: Bringing awareness can sometimes be the best medicine
December 23rd, 2022
OK, Class! Time to Open Your Calendars and Review the Year
December 22nd, 2022
Airway Angioedema Triggered by ACE Inhibitor Not Eased by Berinert
December 15th, 2022
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
December 12th, 2022
Severe Recurrent Abdominal Pain Leads to HAE Type 1 Diagnosis: Case
December 9th, 2022
Detecting Hereditary Angioedema Symptoms Early to Mitigate Flares
December 2nd, 2022
After Suffering a Crippling Loss, Keep Going
November 28th, 2022
Most HAE Patients Treated With Donidalorsen for Year Attack Free
November 25th, 2022
The Best Way to Accentuate the Positive
November 18th, 2022
Why I Fear Sending My Daughter to Slumber Parties
November 17th, 2022
Most HAE Patients Attack-free After Gene-editing Therapy NTLA-200
November 12th, 2022
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
November 11th, 2022
Sharing Duties as a Family Caregiver Is Like Losing a Security Blanket
November 10th, 2022
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
November 10th, 2022
Treatment using CRISPR genome editing alleviates swelling attacks in hereditary angioedema patients
November 9th, 2022
CRISPR Treatment Slows Swelling in Hereditary Angioedema Patients
November 4th, 2022
We Don’t Know What We Don’t Know — But We Can Learn
October 31st, 2022
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
October 27th, 2022
Pregnancy Not Linked to Worse Disease in Women With HAE: Study
October 24th, 2022
Takhyrzo Found to Be Effective HAE Treatment Across Minority Groups
October 21st, 2022
On Bad Weeks, You Need the Best Team Ever
October 20th, 2022
Man’s Only Symptom of HAE Type 2 Is Abdominal Pain: Case Report
October 19th, 2022
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
October 17th, 2022
2 New US CSL Plasma Collection Centers Open to Meet Growing Need
October 14th, 2022
I’m Not in the Business of Raising Champions
October 10th, 2022
FDA Decision Due Next Year on Takhzyro for Children as Young as 2
October 5th, 2022
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
September 26th, 2022
A challenging diagnosis: hereditary angioedema presenting during pregnancy
September 23rd, 2022
The Importance of Staying Aware So That Rare Doesn’t Surprise You
September 22nd, 2022
Takhzyro Use Resulted in Prolonged Dosing Intervals, Fewer Treatment
September 19th, 2022
NTLA-2002 Gene Therapy Safely Prevents HAE Attacks: Trial Data
September 16th, 2022
Coming to Terms With Unrealistic Expectations After an HAE Diagnosis
September 16th, 2022
Intellia offers first look at CRISPR drug for rare swelling disorder
September 15th, 2022
The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack
September 9th, 2022
Even Those Things We Love Can Become an Instant Problem
September 6th, 2022
Investigational CRISPR Therapy Gets Orphan Drug Status for Hereditary Angioedema
September 2nd, 2022
Past Experiences Make Me Wonder About My Daughter’s Future Friendships
August 26th, 2022
To Treat Special Needs, an Average Babysitter Just Isn’t Enough
August 25th, 2022
Garadacimab Effective at Preventing HAE Attacks, Phase 3 Trial Shows
August 22nd, 2022
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
August 19th, 2022
‘Back in the Car, but Out of the Tree’: Addressing Medical Fears With Compassion
August 18th, 2022
CSL gets positive results for preventive treatment in patients with hereditary angioedema
August 17th, 2022
Meet the Expert: Focus on HAE
August 16th, 2022
New Explorer’s career plan? Advocate for those fighting rare diseases
August 16th, 2022
Former high school track athlete in north metro battling rare disease
August 12th, 2022
The Importance of Finding Space for Your Passions
August 11th, 2022
Case Highlights Importance of Distinguishing Types of Angioedema
August 5th, 2022
The Experience of Living in Denial, From Soda to a Diagnosis
August 4th, 2022
Astria Therapeutics Announces Initiation Of Phase 1a Trial Of STAR-0215, A Monoclonal Antibody Inhibitor Of Plasma Kallikrein For Treatment Of Hereditary Angioedema
August 4th, 2022
PAR1 Protein May Be Target for HAE Treatment
July 25th, 2022
Ruconest Works for 1 in 6 With Idiopathic Angioedema in Pilot Study
July 25th, 2022
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215,
a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
July 18th, 2022
Firazyr or Icatibant May, With Caution, Be Safe While Breastfeeding
July 15th, 2022
Understanding My Own Weird Habits Allowed Me to Help My Daughter Relax
July 10th, 2022
A Hollywood ending: How one woman took control of her rare disease and achieved her dream
July 1st, 2022
How Our Daughter Defines Normal With Hereditary Angioedema
July 1st, 2022
Takeda targets younger HAE patients with Phase 3 data for Takhzyro
June 30th, 2022
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
June 30th, 2022
Symptoms of HAE Can Occur Without Swelling Attack: Study
June 20th, 2022
Firazyr Safe for Attacks in Patients With Normal C1-INH Activity
June 17th, 2022
Planning Road Trips Leads to Worry — and Who Needs That?
June 10th, 2022
Navigating Love and Relationships While Caring for a Sick Child
June 9th, 2022
2 More Countries Approve Orladeyo for Preventing HAE Attacks
June 8th, 2022
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
June 1st, 2022
Prophylactic therapy with subcutaneous C1 inhibitor reduces hereditary angioedema attacks
May 25th, 2022
Acute HAE Attack Seen With Rare Stroke-like Symptoms: Case Report
May 23rd, 2022
Use of Haegarda Reduces Swelling Attack Rate, Rescue Medication Use
May 19th, 2022
KalVista’s HAE Treatment KVD900 Now Called Sebetralstat
May 17th, 2022
KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
May 9th, 2022
Dosing Complete in Phase 1/2 1st Group of NTLA-2002 Trial for HAE
April 18th, 2022
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
April 15th, 2022
Because the Other Kids Get Sick, Too
April 12th, 2022
Takeda Touts Positive Pediatric Data in Competitive HAE Space
April 11th, 2022
The Use of 6 Warning Signs May Aid in Improving C1-INH-HAE Diagnosis
April 5th, 2022
The healing power of art
March 30th, 2022
HAEi Global Perspectives Magazine Spring 2022
March 25th, 2022
How I Stopped Forgetting to Remember
March 21st, 2022
Swelling Attacks Down, Quality of Life Up in Donidalorsen Phase 2 Trial
March 18th, 2022
Coming to Terms With Caregiver’s Guilt
March 17th, 2022
Inhibition of Prekallikrein for Hereditary Angioedema
March 17th, 2022
3D Analysis of Facial Features May Help Treat, Diagnose HAE
March 16th, 2022
Antisense Drug Slashed Hereditary Angioedema Attacks in Small Study
March 16th, 2022
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
March 14th, 2022
Astria Anticipates Trial of STAR-0215 in Healthy Volunteers This Year
March 10th, 2022
Takhzyro Found Safe, Effective for HAE Over Long Term in Real-world Study
March 7th, 2022
Orladeyo Shown to Prevent Attacks and Improve Quality of Life in Trial
March 7th, 2022
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
March 4th, 2022
We Forgot to Tell Our Daughter About Her Diagnosis
February 28th, 2022
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
February 25th, 2022
The Tale of Two Truths
February 24th, 2022
BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates
February 21st, 2022
Enrollment Opens in HAERMONY Trial to Test HAE Gene Therapy
February 18th, 2022
Step-ball-Change Into Butterfly Needles
February 14th, 2022
Takhzyro in More Convenient Prefilled Syringe Approved in US for HAE
February 10th, 2022
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
February 10th, 2022
Berinert Prevents Acute Swelling in HAE Patient After Oral Surgery
February 7th, 2022
Changes in Gut Microbiota May Contribute to HAE Attacks
January 27th, 2022
KVD900 Rapidly Suppresses Kallikrein, Phase 1 Studies Show
January 24th, 2022
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
January 24th, 2022
Warning Symptoms May Foretell HAE Attacks, Study Finds
January 20th, 2022
Study shows advances in treatments for patients with angioedema in Puerto Rico
January 20th, 2022
Care May Prevent Airway Swelling in HAE Patients During Surgery
January 17th, 2022
US Patients Underreport Burden of HAE to Their Doctors, Study Says
January 10th, 2022
New Gene Mutation Linked to HAE Type 1 Identified in Spanish Family
January 7th, 2022
An anesthetic experience of hereditary angioedema type I patient undertook total laparoscopic hysterectomy - A case report -
December 16th, 2021
An Evidence Based Therapeutic Approach To Hereditary And Acquired Angioedema
December 16th, 2021
Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient
December 9th, 2021
Highly Unpredictable Rate of Annual Attacks Seen in Certain Patients
December 7th, 2021
COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications
December 2nd, 2021
How do patients and physicians communicate about hereditary angioedema in the United States?
November 15th, 2021
Phase 3 Study of Oral KVD900 as On-Demand Therapy Likely in 2022
November 11th, 2021
Orladeyo Sustainably Lowers HAE Attack Rates, Trial Data Show
November 10th, 2021
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema
November 10th, 2021
HAE Still Drawing Attention From Drugmakers
November 8th, 2021
Patient-collected Blood Samples May Help Predict Acute HAE Attacks
November 7th, 2021
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
October 26th, 2021
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
October 25th, 2021
Patients Say They Want to Switch to Less Frequent Therapies
October 6th, 2021
Optimization of care for patients with hereditary angioedema living in rural areas
October 6th, 2021
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
October 4th, 2021
CAMP4 Platform May Enhance Gene Activity to Therapeutic Levels
October 1st, 2021
Holy Trinity Student and Staff Bake to Raise Funds for HAE
September 30th, 2021
Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks
September 13th, 2021
Cycle Pharmaceuticals Launches Cycle Vita™, a Dedicated Support Platform for Rare Disease Patients
August 30th, 2021
Living with hereditary angioedema (HAE)
August 29th, 2021
7 Questions to Ask Your Doctor About Hereditary Angioedema
August 26th, 2021
Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open
August 19th, 2021
Potential Blood Biomarkers for Types of Angioedema Noted in Study
August 18th, 2021
Your FAQs, Answered: What Is a Hereditary Angioedema Attack?
August 12th, 2021
Takhzyro With Long-term Use Safely Prevent HAE Attacks, Study Finds
August 5th, 2021
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
August 5th, 2021
FDA Approves Combo Kit for Easier At-home Use of Berinert
August 2nd, 2021
Pharvaris Expanding PHVS416 Trial to US, Launching 2nd Study
July 22nd, 2021
Deal Struck to Distribute Ruconest in Middle East, North Africa
July 19th, 2021
Early Phase 1 Data Support PHA121 as Oral HAE Prophylactic
July 15th, 2021
Understanding and Managing Hereditary Angioedema Triggers
July 12th, 2021
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 12th, 2021
Interim Data Support Long-term Safety of Orladeyo for HAE Attacks
July 10th, 2021
New data from the Phase 3 HELP Study™ Open Label Expansion to evaluate the safety and efficacy of TAKHZYRO® (lanadelumab) in patients with hereditary angioedema will be announced at the European Society of Allergy and Clinical Immunology (EAACI) Hybrid Co
July 10th, 2021
America Recognizes Chronic Disease Day 2021 with Good Days
July 10th, 2021
Berotralstat Reduces Hereditary Angioedema Attacks in Phase 3 Trial
July 10th, 2021
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
July 10th, 2021
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
July 9th, 2021
Boston Bridges Light Up Orange & White for Chronic Disease Day & Good Days
July 9th, 2021
Children's Book Series Helps Kids Cope with Hereditary Angioedema
July 8th, 2021
Companies Join to Advance OTL-105, Potential Gene Therapy for HAE
July 1st, 2021
Orchard Therapeutics Inks Strategic Deal to Develop HSC Gene Therapy for Hereditary Angioedema
June 30th, 2021
Psychosocial burden of type 1 and 2 hereditary angioedema: A single-center Canadian cohort study
June 28th, 2021
In Major CRISPR Milestone, INTELLIA Successfully Edits Genes Inside Body
June 14th, 2021
Oral PHA121 May Lead to Faster, More Durable Effects Than Firazyr
June 11th, 2021
New Children’s Book Series Helps Kids Cope with Ultra-Rare Chronic Condition
June 5th, 2021
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
May 25th, 2021
BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo
May 24th, 2021
Pharma, Patient Associations Join Efforts for HAE Awareness Day
May 18th, 2021
Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
May 17th, 2021
Pharming celebrates the 10th annual "hae day :-)
May 10th, 2021
Japanese Researchers Identify New Gene Mutation Linked to HAE
May 10th, 2021
The Genetics of Hereditary Angioedema: A Review
May 9th, 2021
The Genetics of Hereditary Angioedema: A Review
May 3rd, 2021
Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks
April 29th, 2021
Supporters ‘Take Next Step’ Toward HAE Awareness Day on May 16
April 23rd, 2021
Prophylactic treatment in hereditary angioedema is associated with reduced anxiety in patients in Leipzig, Germany
April 19th, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
April 13th, 2021
Impact of lanadelumab on health related quality of life in patients with hereditary angioedema in the HELP study
April 12th, 2021
Life Quality Gains Evident With Newer Preventive HAE Therapies, Survey Finds
March 29th, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
March 23rd, 2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women
March 22nd, 2021
Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials
March 18th, 2021
Orladeyo Now Available in France Via Early Access Program
March 17th, 2021
Patient-researcher collaboration proves to be a win-win, Japanese study shows
March 12th, 2021
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
March 11th, 2021
Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema
March 11th, 2021
Screening for Plasminogen Mutations in Hereditary Angioedema Patients Genes Article MDPI
March 11th, 2021
Biocryst’s berotralstat granted early access for HAE in France
March 11th, 2021
Orphan product designation requests climb in the US, remain steady in the EU
March 11th, 2021
First Patient Dosed in Phase 2 Trial Testing PHVS416 for HAE Attacks
March 8th, 2021
Interim Trial Data of Gene-editing Therapy NTLA-2001 Expected This Year
March 5th, 2021
Long-term Haegarda Found to Improve Quality of Life in HAE Patients
March 3rd, 2021
BioCryst Pharma (BCRX) Submits MAA for UK Approval of ORLADEYO, an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
March 1st, 2021
Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks
February 26th, 2021
Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers
February 25th, 2021
Oral Hereditary Angioedema Treatment Provides Effective Bradykinin-Inhibiting Concentrations
February 23rd, 2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women
February 19th, 2021
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
February 18th, 2021
HAE Patients in US Favored Oral Prophylactic in 2018 Survey
February 15th, 2021
Stress Can Affect Patients’ Mental Health, How They Manage Their Care
February 8th, 2021
Menopause Found to Not Worsen HAE in Most Women
February 8th, 2021
Optimal Management of HAE: Shared Decision Making
January 9th, 2021
Psychological processes in the experience of hereditary angioedema in adult patients: an observational study
December 3rd, 2020
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
December 1st, 2020
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults
November 20th, 2020
New Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1 INH Deficiency When Choosing an HAE Therapy
October 15th, 2020
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise
September 29th, 2020
U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
May 15th, 2020
BioCryst Celebrates HAE Patients with HAE Global Walk
May 4th, 2020
CSL Behring is Committed to Supporting Patients
May 1st, 2020
Pharming to Support Patients Continuity in Care
April 22nd, 2020
Takeda Expands Patient Assistance in the U.S. During COVID-19 Crisis
April 21st, 2020
Pharming reports encouraging results from use of RUCONEST® in COVID-19 patients
April 6th, 2020
Mensaje de la Directora de Salud de la HAEA, Lois Perry
April 6th, 2020
A Message from the Director of HAE Health Lois Perry
April 6th, 2020
GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY
March 19th, 2020
An Important Message Regarding HAEA Upcoming Events
March 18th, 2020
How Our Pharmaceutical Companies Are Managing the Coronavirus Situation.
March 6th, 2020
A Message from HAEA Nurse Case Manager Troyce Venturella
January 13th, 2020
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise
November 27th, 2018
JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema
August 23rd, 2018
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
June 21st, 2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients
May 16th, 2018
KalVista Pharmaceuticals Recognizes HAE Day
April 9th, 2018
HAEA comments on ICER HAE therapy assessment
February 25th, 2018
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
February 15th, 2018
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
January 24th, 2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
January 22nd, 2018
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
January 8th, 2018
A Big Pharma-funded charity that helps patients pay for drugs just sued the government
January 5th, 2018
KalVista Pharmaceuticals Commences Two Clinical Trials
September 29th, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema
September 14th, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results
September 11th, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
September 11th, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE
September 5th, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
July 26th, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet
July 23rd, 2017
FDA Approves HAEGARDA® King Of Prussia, PA
June 22nd, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease
May 24th, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
May 24th, 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
April 13th, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
March 23rd, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients
October 1st, 2016
Elucidating the Mechanism of Gain of Toxic Function From Mutant C1 Inhibitor Proteins in Hereditary Angioedema
April 12th, 2016
How we manage persons with hereditary angioedema
Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers
